Connect with us

News

Breath-based cancer test begins clinical trials in the UK

Published

on

The Cancer Research UK Cambridge Center has begun clinical trials for Cambridge-based Owlstone Medical’s Breath Biopsy® technology, a breathalyzer-type test that analyzes patients’ exhalations for biomarkers indicative of cancer. Samples from 1500 people, to include healthy participants as controls, will be used to determine whether the types of breath molecules assessed can positively identify both the presence of cancer and its type. The earlier cancer can be detected, the better the potential outcome for patients. Thus, noninvasive testing technology like Breath Biopsy® would be a very useful tool in cancer treatment.

The Breath Biopsy® test will search for what are called volatile organic compounds (VOCs), i.e., emissions triggered by cellular metabolic processes that enter the bloodstream. These act as biomarkers for cancer due to changes the disease makes to the body or made to the cancer growth itself. For example, during tumor growth, gene or protein changes can damage cell membranes and then release molecular byproducts specific to that type of tumor, VOCs, which are circulated in the lungs and exhaled. Normal human breath contains hundreds of VOCs from the body’s regular metabolic processes; however, certain types have been specifically linked to cancers, and researchers have been working to narrow the parameters to make clinically-useful tests, as is being done with Owlstone’s technology.

An overview of the VOC process in the body. | Credit: Owlstone Medical.

Early detection of cancer is one of the most significant tools that can impact its lethality, namely because most cancers aren’t found until they are at an advanced stage. Certain cancers, such as ovarian, lung, pancreatic, and colorectal, are hard to detect in their early stages, making survival rates low from the progression at the time of discovery. Also, tests for the presence of cancers are often invasive and expensive. Tools for accurate breath analysis identifying specific cancer biomarkers would provide significant improvement on both of these counts.

According to the National Cancer Institute, an estimated 1,735,350 new cases of cancer were diagnosed in 2018 in the United States, and 609,640 people died from the disease. Worldwide, that number is around 9 million per year. Statistics like these make the field of cancer research ripe for opportunities to address its numerous challenges with emerging and developing technologies.

Biotech has embraced cancer research and treatment as well as other fields not traditionally geared towards biological research. For example, artificial intelligence is aiding in cancer identification and prediction. Of further interest, genetic engineering is addressing environmental toxins known to cause cancer, and 3D printing is even being used in space to assess radiation’s effects on living tissue, a known factor in skin cancers. The push towards putting more humans in space will continue to expand the knowledge base in this area as science by NASA and similar national agencies and partners explore these issues as they relate to off-planet travel.

Advertisement

Accidental computer geek, fascinated by most history and the multiplanetary future on its way. Quite keen on the democratization of space. | It's pronounced day-sha, but I answer to almost any variation thereof.

Advertisement
Comments

Elon Musk

SpaceX to launch military missile tracking satellites through new Space Force contract

SpaceX wins a $178.5M Space Force contract to launch missile tracking satellites starting in 2027.

Published

on

By

Space Force officials say the Falcon 9 booster pictured here in SpaceX's rocket factory will have to wait a few months longer for its launch debut. (SpaceX)

The U.S. Space Force awarded SpaceX a $178.5 million task order on April 1, 2026 to launch missile tracking satellites for the Space Development Agency. The contract, designated SDA-4, covers two Falcon 9 launches beginning in Q3 2027, one from Cape Canaveral Space Force Station in Florida and one from Vandenberg Space Force Base in California. The satellites, built by Sierra Space, are designed to bolster the nation’s ability to detect and track missile threats from orbit.

The award falls under the National Security Space Launch Phase 3 Lane 1 program, which Space Force uses to move payloads to orbit on faster timelines and at more competitive prices. “Our Lane 1 contract affords us the flexibility to deliver satellites for our customers, like SDA, more easily and faster than ever before to all the orbits our satellites need to reach,” said Col. Matt Flahive, SSC’s system program director for Launch Acquisition, in the official press release.

SpaceX is quietly becoming the U.S. Military’s only reliable rocket

The SDA-4 contract is the latest in a long string of national security wins for SpaceX. As Teslarati reported last month, the Space Force recently shifted a GPS III satellite launch from ULA’s Vulcan rocket to SpaceX’s Falcon 9 after a significant Vulcan booster anomaly grounded ULA’s military missions indefinitely. That move made it four consecutive GPS III satellites transferred to SpaceX after contracts were originally awarded to its competitor.

Advertisement

This didn’t come without a fight and dates back years. SpaceX originally had to sue the Air Force in 2014 for the right to compete for national security launches, at a time when United Launch Alliance held a near monopoly on the market. Since then, the company has steadily displaced ULA as the dominant provider, and last year the Space Force confirmed SpaceX would handle approximately 60 percent of all Phase 3 launches through 2032, worth close to $6 billion.

With missile defense satellites now part of its launch manifest alongside GPS, communications, and reconnaissance payloads, SpaceX is giving hungry investors something to chew on before its imminent IPO.

Continue Reading

Elon Musk

Tesla’s Q1 delivery figures show Elon Musk was right

On the surface, the numbers reflect a mature EV market facing competition, softening demand, and the loss of certain incentives. Yet they also quietly validate a prediction Elon Musk has repeated for years: Tesla’s traditional auto business is becoming far less central to the company’s future.

Published

on

Credit: Grok

Tesla reported its Q1 delivery figures on Thursday, and the figures — solid but unspectacular — show that CEO Elon Musk was right about what the company’s most important production and division would be.

We are seeing that shift occur in real time.

Tesla delivered 358,023 vehicles in the first quarter of 2026, according to the company’s official report released April 2.

The figure represents modest year-over-year growth of roughly 6 percent from Q1 2025’s 336,681 deliveries but a sharp sequential drop from Q4 2025’s 418,227. Production reached 408,386 vehicles, while energy storage deployments hit 8.8 GWh.

Advertisement

On the surface, the numbers reflect a mature EV market facing competition, softening demand, and the loss of certain incentives. Yet they also quietly validate a prediction Elon Musk has repeated for years: Tesla’s traditional auto business is becoming far less central to the company’s future.

Musk has long argued that vehicles alone will not define Tesla’s value.

Optimus Will Be Tesla’s Big Thing

In September 2025, Musk stated bluntly on X that “~80% of Tesla’s value will be Optimus,” the company’s humanoid robot.

He has described Optimus as potentially “more significant than the vehicle business over time.” Those comments were not abstract futurism. In January 2026, during the Q4 2025 earnings call, Musk announced the end of Model S and X production, framing it as an “honorable discharge,” he called it.

Advertisement

The Fremont factory space, once dedicated to those flagship sedans, is being converted into an Optimus manufacturing line, with a long-term target of one million robots per year from that single facility alone.

Advertisement

The Q1 2026 numbers arrive at precisely the moment this strategic pivot is accelerating. Model 3 and Y deliveries totaled 341,893 units, while “other models” (including Cybertruck, Semi, and the final wave of S/X) added 16,130.

Growth is no longer explosive because Tesla is no longer chasing volume at all costs. Instead, the company is reallocating capital and factory floor space toward autonomy, energy storage, and robotics, businesses Musk believes will command far higher margins and enterprise value than incremental car sales.

Delivery Hits and Misses are Becoming Less Important

Wall Street’s pre-release consensus had pegged deliveries near 365,000. Coming in below that estimate might have rattled investors focused solely on automotive metrics. Yet Musk’s thesis has never been about maximizing quarterly vehicle shipments.

Tesla, he has insisted, “has never been valued strictly as a car company.”

Advertisement

The modest Q1 auto performance, paired with the deliberate wind-down of legacy programs and the ramp of Optimus, underscores that point. While EV demand stabilizes, Tesla is building the infrastructure for Robotaxis and humanoid robots that could dwarf today’s car business.

Tesla reports Q1 deliveries, missing expectations slightly

The future is here, and it is happening. It’s funny to think about how quickly Tesla was able to disrupt the traditional automotive business and force many car companies to show their hand. But just as fast as Tesla disrupted that, it is now moving to disrupt its own operation.

Cars, once the only recognizable and widely-known division of Tesla, is now becoming a background effort, slowly being overtaken by the company’s ambitions to dominate AI, autonomy, and robotics for years to come.

Advertisement

Critics may still view the shift as risky or premature. But the Q1 figures, solid but unspectacular in the auto segment, illustrate exactly what Musk has been signaling: the era when Tesla’s valuation rose and fell with every Model Y delivery is ending.

The company’s long-term bet is on AI-driven products that turn vehicles into high-margin robotaxis and factories into robot foundries. Thursday’s delivery report did not just meet the market’s tempered expectations; it proved Elon Musk was right all along.

The car business, once everything, is quietly becoming an important piece of a much larger puzzle.

Advertisement
Continue Reading

Investor's Corner

Tesla reports Q1 deliveries, missing expectations slightly

The figure, however, fell short of Wall Street’s consensus estimate of 365,645 units, reflecting ongoing headwinds in the global EV market.

Published

on

Credit: Tesla

Tesla reported deliveries for the first quarter of 2026 today, missing expectations set by Wall Street analysts slightly as the company aims to have a massive year in terms of sales, along with other projects.

Tesla delivered 358,023 vehicles in the first quarter of 2026, marking a 6.3 percent increase from 336,681 vehicles in Q1 2025.

The figure, however, fell short of Wall Street’s consensus estimate of 365,645 units, reflecting ongoing headwinds in the global EV market. Production reached approximately 362,000 vehicles, with Model 3 and Model Y accounting for the vast majority. The results come as Tesla navigates softening demand, intensifying competition in China and Europe, and the expiration of key U.S. federal tax incentives.

Energy storage deployments provided a bright spot, hitting a record 8.8 GWh in Q1. This underscores the accelerating momentum in Tesla’s energy segment, which has become a critical growth driver even as automotive volumes stabilize.

Advertisement

Year-over-year, the energy business continues to outpace vehicle sales, with analysts noting strong backlog demand for Megapack systems amid rising grid-scale needs for renewables and AI data centers.

Looking ahead, analysts project full-year 2026 vehicle deliveries in the range of 1.69 million units—a modest 3-5% rise from roughly 1.64 million in 2025.

Growth is expected to accelerate in the second half as production ramps and new incentives emerge in select markets. However, risks remain: persistent high interest rates, price competition from legacy automakers and Chinese EV makers, and potential margin pressure could cap upside.

Tesla has not issued official full-year guidance, but executives have signaled confidence in sequential quarterly improvements driven by cost reductions and refreshed lineups.

Advertisement

By the end of 2026, Tesla plans several major product launches to reignite momentum. The refreshed Model Y, including a new 7-seater variant already rolling out in select markets, is expected to boost family-oriented sales with updated styling, efficiency gains, and interior enhancements.

Autonomous ambitions remain central to Tesla’s mission, and that’s where the vast majority of the attention has been put. Volume production of the Cybercab (Robotaxi) is targeted to begin ramping in 2026, potentially unlocking new revenue streams through unsupervised Full Self-Driving (FSD) deployment.

A next-generation affordable EV platform, possibly under $30,000, is also in advanced planning stages for 2026 or 2027 introduction. On the energy front, the Megapack 3 and larger Megablock systems will drive further deployment scale.

While Q1 highlights transitional challenges in autos, Tesla’s diversified roadmap, spanning refreshed consumer vehicles, commercial trucks, Robotaxis, and explosive energy growth, positions the company for a stronger second half and beyond. Investors will watch Q2 closely for signs of sustained recovery, especially with new vehicles potentially on the horizon.

Advertisement
Continue Reading